Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights


Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024 Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024

See the rest here:
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

Related Posts